EGFR and head and neck cancer: Sapitinib, a ‘quinazoline small’ molecule, showed the most promising results, with EC50 concentrations in the nanomolar range in the four ‘responsive’ lines, which were comparable to those shown in non-small cell lung cancer (NSCLC) and head and neck cancer cell lines designated as EGFR-sensitive.